AbbVie Inc (ABBV)vsAlamar Biosciences, Inc. Common Stock (ALMR)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ALMR
Alamar Biosciences, Inc. Common Stock
$20.80
+1.41%
HEALTHCARE · Cap: $1.52B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 71977% more annual revenue ($62.82B vs $87.16M). ABBV leads profitability with a 5.8% profit margin vs -49.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ALMR
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ALMR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 98.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -33.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ALMR
The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 98.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ALMR
The primary concerns for ALMR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while ALMR is a hypergrowth play — different risk/reward profiles.
ALMR is growing revenue faster at 98.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 24/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alamar Biosciences, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases, leveraging its proprietary technologies to enhance patient care and treatment outcomes. The company's advanced platform offers rapid and accurate testing capabilities aimed at significantly improving clinical decision-making processes. With a strong commitment to research and development, Alamar is poised to address unmet medical needs within the healthcare sector, presenting an attractive opportunity for institutional investors looking to capitalize on the growth potential in the diagnostics market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?